LAURENT FAVRE, M.D.; MICHEL B. VALLOTTON, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The calcium antagonist nifedipine has been shown to suppress symptoms in two patients with pheochromocytoma (1, 2) while decreasing urinary norepinephrine and vanillylmandelic acid levels in one (1) and without changing plasma catecholamine levels in the other (2). To compare the therapeutic effects of Ca2+ antagonism on the endocrine secretion and the vascular action of catecholamines in two normotensive patients with pheochromocytoma, we assessed the ability of nifedipine to suppress the pressor responses to a provocative test with the dopamine antagonist metoclopramide (3).
A 35-year-old man had an adrenal pheochromocytoma secreting epinephrine and norepinephrine. Because his basal
FAVRE L, VALLOTTON MB. Nifedipine in Pheochromocytoma. Ann Intern Med. 1986;104:125. doi: 10.7326/0003-4819-104-1-125_1
Download citation file:
Published: Ann Intern Med. 1986;104(1):125.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use